These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 17042738)

  • 1. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
    Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
    J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
    J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
    Ganapathy A; Nieves JW; Keaveny TM; Cosman F
    Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.
    Imai K; Ohnishi I; Matsumoto T; Yamamoto S; Nakamura K
    Osteoporos Int; 2009 May; 20(5):801-10. PubMed ID: 18800178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
    J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
    Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.
    Rehman Q; Lang TF; Arnaud CD; Modin GW; Lane NE
    Osteoporos Int; 2003 Jan; 14(1):77-81. PubMed ID: 12577188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.
    Borggrefe J; Graeff C; Nickelsen TN; Marin F; Glüer CC
    J Bone Miner Res; 2010 Mar; 25(3):472-81. PubMed ID: 19778182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
    Wermers RA; Recknor CP; Cosman F; Xie L; Glass EV; Krege JH
    Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.